Hospitals, insurance companies, doctors, patients, and generic pharmaceutical companies would all benefit from discoveries about the efficacy of repurposed drugs. Branded pharmaceutical companies always benefit when their legacy drugs find a secondary purpose after patents expire. Today, our government funding and agency actions are not aligned to support such research, and there is no concerted advocacy campaign to build it.
Early in the COVID pandemic, there was great interest in this approach, yet with the advent of a preference for vaccines, the resources and energy previously allocated to these efforts were diverted.
This organization will guide a future framework to test repurposed drugs and treatments that can model clinical benefits and cost savings of the benefits of cheaper generic therapies.
We will organize a call to action for a new public-private partnership to conduct a sustained, independent, systematic study that complements FDA review, clinical practice, and the role of natural immunity in health. The insights from this initiative will inform public and clinical understanding of how readily available and affordable medicines can address numerous illnesses, bolster natural immunity, and improve overall health.
